These compounds exhibit potent and selective inhibition of both EZH2 and EZH1, effectively reducing H3K27me3 levels, and have demonstrated significant anti-tumor activity against diffuse large B-cell lymphoma cells with gain-of-function mutations. Here, EZH2 is linked to neoplasm.